Abbott and Novo expand partnership to launch Plosbrio® broadening access to semaglutide for advanced diabetes care across Asia Pacific
Abbott and Novo have expanded their partnership to launch Plosbrio. This product provides semaglutide for advanced type 2 diabetes care. The collaboration uses Novo's expertise in GLP-1 therapies and diabetes medicines. Abbott will handle the promotion and distribution of the therapy across several Asia Pacific countries. Plosbrio is designed to offer cardiovascular and kidney benefits. It also provides proven HbA1c benefits for patients.
The collaboration combines Novo’s leadership in diabetes care medicines and GLP-1 therapies with Abbott’s extensive healthcare and commercial footprint across the region Abbott will promote and distribute Plosbrio® (semaglutide) across a number of Asia Pacific countries, helping expand access to advanced type 2 diabetes care therapies Plosbrio® offers proven HbA1c, cardiovascular and kidney benefits for […]